Gujarat Terce Laboratories share price
BSE: 524314Pharmaceuticals & BiotechnologySmall Cap
Last close ₹34.13down ₹2.78 (7.53%)
Share price at the BSE close on 23 Oct 2026. Previous close ₹36.91.
52-week range of traded prices to 23 Oct 2026
₹29.00Low, 30 Mar 2026₹53.49High, 23 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹27 Cr3,856th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 7 Aug 2026
- 12.7
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹0.45 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 10.5
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 30 May 2026
- 2.7
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 7 Aug 2026
- 25.8%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹0.45 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 31.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 7 Aug 2026
- 25.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 30 May 2026
- 0.13
- Volume, BSEVolume. Shares traded on the last trading day.
- 3,356
Results
Standalone; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 7 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹9.00 Crdown 21.03%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹0.18 CrQuarter to Mar 2026: ₹0.10 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- −2.0%
Revenue by year
Peak revenue ₹50 Cr, year to Mar 2025
Net profit by year, a loss in red
- Net profit
- Loss
Back to profit in the year to Mar 2026, ₹2.20 CrA loss in 4 of the 10 years shown
| ₹ crore | Sep 2024Filed 28 Oct | Dec 2024Filed 4 Feb | Mar 2025Filed 12 Jun | Jun 2025Filed 11 Aug | Sep 2025Filed 28 Nov | Dec 2025Filed 4 Feb | Mar 2026Filed 30 May | Jun 2026Filed 7 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 13.3 | 12.7 | 12.3 | 10.9 | 12.9 | 12.3 | 11.4 | 9.0 |
| Net profit | 1.5 | 1.0 | −3.4 | 0.0 | 1.4 | 0.8 | 0.1 | −0.2 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 11.1% | 7.9% | −27.5% | −0.4% | 10.9% | 6.2% | 0.9% | −2.0% |
Standalone. The last eight quarters. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceutical, which carries all its revenue.
Valuation
Today, against the company's own history. Dividend yield is not shown: no dividend in the years on record.PE ratio and valuation history
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 36% of 1,179 trading days over the last 5 years.
LowestHighest
Its median3.4Industry median2.9
EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.7.6
At or below today's level on 16% of 661 trading days over the last 3 years.
LowestHighest
Its median10.7Industry median18.7
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −49.5% | – | – | 0.0% |
| 3 years | +22.9% | – | – | 0.0% |
| 5 years | +34.7% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 1, 3 and 5 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Gujarat Terce Laboratories in market cap. 2 companies in the table last traded before then: their rows are priced on their last trade.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Chandra Bhagat PharmaCBPL | 29 | 10.4 | 0.9 | – | +34.1% | +229.5% | 9.0% | – | 0.00% |
 Goldline PharmaceuticalGLPL | 29 | 7.0 | 2.0 | – | – | – | 28.9% | – | 0.00% |
 Sunrest LifescienceSUNREST | 29 | 7.0 | – | – | – | – | 22.4% | – | 0.00% |
 Bacil PharmaBACPHAR | 29 | – | 1.1 | – | – | – | – | −0.7% | 0.00% |
 Lasa SupergenericsLASA | 25 | – | 0.5 | – | −95.2% | – | −24.8% | −24.8% | 0.00% |
 Walpar NutritionsWALPAR | 25 | 9.9 | 1.3 | – | +9.8% | −42.7% | 14.0% | – | 0.00% |
 Welcure Drugs & PharmaceuticalsWELCURE | 22 | – | – | – | – | – | – | – | 0.00% |
 Ishita Drugs & IndustriesISHITADR | 21 | 29.6 | 1.8 | 24.8 | −28.6% | −31.0% | 6.3% | 5.3% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Aug 2026
21 Aug · Meeting
21 Aug · Meeting
21 Aug · Management
7 Aug · Results
7 Aug · Results
Gujarat Terce Laboratories share price by year
Each calendar year to 2025.Gujarat Terce Laboratories share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 43.50 | −48.7% | 84.85 | 38.36 |
| 2024 | 84.80 | +197.6% | 91.68 | 28.44 |
| 2023 | 28.49 | +56.1% | 32.00 | 15.30 |
| 2022 | 18.25 | +0.1% | 42.35 | 15.25 |
| 2021 | 18.24 | +108.5% | 19.45 | 6.80 |
| 2020 | 8.75 | +15.0% | 10.25 | 6.10 |
| 2019 | 7.61 | −27.4% | 9.96 | 5.91 |
| 2018 | 10.48 | −29.7% | 15.10 | 8.16 |
| 2017 | 14.91 | +16.9% | 18.20 | 7.09 |
| 2016 | 12.75 | +5.0% | 14.50 | 6.60 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. The 2018 close is its last trade, on 13 Dec 2018.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on BSE.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 23 Oct 2026 | 37.65 | 38.40 | 33.77 | 34.13 | 37.46 | 3,356 |
| 22 Oct 2026 | 34.60 | 36.94 | 34.60 | 36.91 | 36.19 | 783 |
| 21 Oct 2026 | 35.05 | 35.05 | 32.36 | 34.69 | 34.10 | 466 |
| 19 Oct 2026 | 36.50 | 37.49 | 34.83 | 35.05 | 35.41 | 15,965 |
| 16 Oct 2026 | 38.11 | 40.00 | 35.11 | 36.68 | 37.56 | 8,003 |
| 15 Oct 2026 | 41.00 | 41.00 | 38.11 | 38.91 | 40.66 | 2,109 |
| 14 Oct 2026 | 40.83 | 41.47 | 38.65 | 40.49 | 40.82 | 137 |
| 13 Oct 2026 | 42.57 | 42.57 | 38.65 | 40.83 | 40.21 | 1,362 |
| 12 Oct 2026 | 36.40 | 43.00 | 36.00 | 41.54 | 41.21 | 10,687 |
| 9 Oct 2026 | 36.20 | 36.20 | 35.25 | 36.20 | 35.91 | 649 |
Prices in ₹ per share as traded, not adjusted.
Company details
- Legal name
- Gujarat Terce Laboratories Ltd
- BSE code
- 524314
- ISIN
- INE499G01013
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Jul 1993
- Face value
- ₹10
- CIN
- L24100GJ1985PLC007753
- Corporate identity number, the registrar of companies' code for it